Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs ...

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as a backer. By Michael J. de la Merced Reporting from London Over the ...